Biofrontera Inc.
Biofrontera Inc. develops and commercializes pharmaceutical products for treating dermatological conditions, primarily through photodynamic therapy.
Biofrontera Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $13.8M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 11, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Spoken Alpha tracks BFRI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BFRI.
$ curl https://api.spokenalpha.com/v1/companies/BFRIFAQ
Spoken Alpha indexes BFRI's earnings call transcripts at https://spokenalpha.com/companies/BFRI. Each call links to attributed speakers and parsed analyst Q&A. Biofrontera Inc.'s own investor relations page is at https://investors.biofrontera-us.com/.
Biofrontera Inc. (BFRI) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
Biofrontera Inc. (BFRI) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | — | $-0.04 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-0.41 | $-0.05 | -100.0% | $10.1M | — | — | EODHD |
| Q4 FY2025 | 2026-03-18 | $0.50 | $0.10 | +100.0% | $17.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.62 | $-0.57 | -8.8% | $7.0M | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.57 | $-0.57 | 0.0% | $9.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.51 | $-0.29 | -75.3% | $8.6M | — | — | EODHD |
| Q4 FY2024 | 2025-03-12 | $-0.23 | $-0.07 | -100.0% | $12.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-0.81 | $-0.83 | +1.9% | $9.0M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.05 | $-0.77 | +93.5% | $7.8M | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-2.88 | $-1.17 | -100.0% | $7.9M | — | — | EODHD |
| Q4 FY2023 | 2024-03-14 | $1.65 | $-1.19 | +100.0% | $10.6M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-4.64 | $-3.78 | -22.8% | $8.9M | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-7.23 | $-4.61 | -56.8% | $5.8M | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-0.28 | $-0.19 | -47.4% | $8.7M | — | — | EODHD |
| Q4 FY2022 | 2023-03-07 | $-0.14 | $-0.11 | -27.3% | $10.1M | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.11 | $-0.29 | +62.1% | $4.3M | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.05 | $-0.34 | +85.3% | $4.5M | — | — | EODHD |
| Q1 FY2022 | 2022-04-07 | $-0.15 | $-0.18 | +16.7% | $9.8M | — | — | EODHD |
| Q4 FY2021 | 2021-12-30 | $-0.15 | $-0.18 | +16.7% | $9.2M | — | — | EODHD |
| Q3 FY2021 | 2021-11-29 | $-2.00 | $-0.58 | -100.0% | $4.3M | — | — | EODHD |
Source: EODHD. BFRI reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.13 | $3.62 | +41.7% | -3.6% | -5.6% |
| Q4 FY2026 | $5.48 | $3.67 | +49.4% | -3.0% | -3.9% |
| Q3 FY2026 | $5.76 | $3.82 | +50.7% | +1.0% | +0.8% |
| Q2 FY2026 | $5.21 | $3.57 | +45.8% | +0.8% | +1.3% |
| Q1 FY2025 | $5.56 | $3.75 | +48.2% | +2.1% | +1.7% |
CFO since 2022 • 13/16 beats (81%) • last guidance cut Q1 FY2026
| Q4 FY2025 |
| $5.07 |
| $3.65 |
| +38.9% |
| +5.1% |
| +2.6% |
| Q3 FY2025 | $5.73 | $3.85 | +48.8% | +4.9% | +2.9% |
| Q2 FY2025 | $5.01 | $3.64 | +37.6% | -4.4% | -6.2% |
| Q1 FY2024 | $5.14 | $3.67 | +40.1% | -3.2% | -4.4% |
| Q4 FY2024 | $5.30 | $3.85 | +37.6% | +5.6% | +7.2% |